Neon Therapeutics to present data from NT-001 at ESMO
Neon Therapeutics announced that updated data from NT-001, its ongoing Phase 1b clinical trial evaluating NEO-PV-01 in the metastatic setting, will be presented in an upcoming oral presentation at the European Society for Medical Oncology, or ESMO.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.